JP2020501510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501510A5 JP2020501510A5 JP2019515416A JP2019515416A JP2020501510A5 JP 2020501510 A5 JP2020501510 A5 JP 2020501510A5 JP 2019515416 A JP2019515416 A JP 2019515416A JP 2019515416 A JP2019515416 A JP 2019515416A JP 2020501510 A5 JP2020501510 A5 JP 2020501510A5
- Authority
- JP
- Japan
- Prior art keywords
- anchor domain
- binding
- polypeptide
- tnfα
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 69
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 69
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 69
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 52
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 52
- 230000001225 therapeutic effect Effects 0.000 claims description 48
- 102000037865 fusion proteins Human genes 0.000 claims description 30
- 108020001507 fusion proteins Proteins 0.000 claims description 30
- 102000008186 Collagen Human genes 0.000 claims description 26
- 108010035532 Collagen Proteins 0.000 claims description 26
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 26
- 229920001436 collagen Polymers 0.000 claims description 26
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 26
- 102000004889 Interleukin-6 Human genes 0.000 claims description 24
- 108090001005 Interleukin-6 Proteins 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 24
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 22
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims description 22
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 22
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims description 22
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 20
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 20
- 239000005557 antagonist Substances 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 108010038196 saccharide-binding proteins Proteins 0.000 claims description 18
- 102000003814 Interleukin-10 Human genes 0.000 claims description 16
- 108090000174 Interleukin-10 Proteins 0.000 claims description 16
- 108090001090 Lectins Proteins 0.000 claims description 16
- 102000004856 Lectins Human genes 0.000 claims description 16
- 239000002523 lectin Substances 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- -1 P144 Proteins 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 208000006069 Corneal Opacity Diseases 0.000 claims description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 6
- 206010013774 Dry eye Diseases 0.000 claims description 6
- 102000015696 Interleukins Human genes 0.000 claims description 6
- 108010063738 Interleukins Proteins 0.000 claims description 6
- 231100000269 corneal opacity Toxicity 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000037390 scarring Effects 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 241000193403 Clostridium Species 0.000 claims description 4
- 102000029816 Collagenase Human genes 0.000 claims description 4
- 108060005980 Collagenase Proteins 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 229960002424 collagenase Drugs 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 241000224422 Acanthamoeba Species 0.000 claims description 2
- 108010062580 Concanavalin A Proteins 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 101710120037 Toxin CcdB Proteins 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 29
- 238000004873 anchoring Methods 0.000 claims 3
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 108010084553 jacalin Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 108010047303 von Willebrand Factor Proteins 0.000 description 10
- 102100036537 von Willebrand factor Human genes 0.000 description 10
- 229960001134 von willebrand factor Drugs 0.000 description 10
- 102000004551 Interleukin-10 Receptors Human genes 0.000 description 2
- 108010017550 Interleukin-10 Receptors Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662396958P | 2016-09-20 | 2016-09-20 | |
| US62/396,958 | 2016-09-20 | ||
| PCT/US2017/052288 WO2018057522A1 (en) | 2016-09-20 | 2017-09-19 | Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020501510A JP2020501510A (ja) | 2020-01-23 |
| JP2020501510A5 true JP2020501510A5 (https=) | 2020-10-08 |
Family
ID=61690642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515416A Pending JP2020501510A (ja) | 2016-09-20 | 2017-09-19 | 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200331984A1 (https=) |
| EP (1) | EP3516063A4 (https=) |
| JP (1) | JP2020501510A (https=) |
| AU (1) | AU2017330565A1 (https=) |
| WO (1) | WO2018057522A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019232729B2 (en) * | 2018-03-05 | 2024-08-08 | The University Of Chicago | Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines |
| JP2021516966A (ja) | 2018-03-09 | 2021-07-15 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 組織への生物学的薬物の送達 |
| WO2021081345A1 (en) * | 2019-10-25 | 2021-04-29 | Mayo Foundation For Medical Education And Research | Bi-peptide with affinity to extracellular matrix proteins or cells and to growth factors for tissue healing and regeneration |
| AU2021289613A1 (en) * | 2020-06-12 | 2022-12-15 | Monash University | IL-1 receptor antagonist (IL-1 Ra) fusion proteins binding to extracellular matrix |
| BR112023007024A2 (pt) * | 2020-10-15 | 2023-10-03 | Univ Northeastern | Células modificadas para produção aumentada de colágeno |
| WO2023215269A1 (en) * | 2022-05-06 | 2023-11-09 | The Regents Of The University Of California | Lacripep promotes neuroregeneration and maintains epithelial progenitor cell identity |
| JP2025537248A (ja) * | 2022-11-08 | 2025-11-14 | ネクストキュア インコーポレイテッド | 免疫チェックポイント阻害剤及び細胞外マトリックス成分結合剤の併用療法及びその使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387663B1 (en) * | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
| US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
| KR20120063475A (ko) * | 2009-07-29 | 2012-06-15 | 글락소 그룹 리미티드 | 항-ｔｇｆ-베타 수용체 타입 ⅱ 단일 도메인 항체 |
| CA2827443C (en) * | 2011-02-15 | 2021-07-06 | Vaxiion Therapeutics, Inc. | Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
| CN104619727B (zh) * | 2012-06-25 | 2019-04-05 | 布里格姆及妇女医院股份有限公司 | 靶向治疗 |
| WO2014089267A1 (en) * | 2012-12-05 | 2014-06-12 | Eleven Biotherapeutics, Inc. | Galectin-3 fusion proteins |
| US20150328044A1 (en) * | 2012-12-19 | 2015-11-19 | Glaxo Group Limited | Guide Device For A Liquid Dispenser |
| RS61778B1 (sr) * | 2013-05-06 | 2021-06-30 | Scholar Rock Inc | Kompozicije i postupci za modulaciju faktora rasta |
| WO2014197485A1 (en) * | 2013-06-03 | 2014-12-11 | Ansun Biopharma, Inc. | Anti-viral therapeutic for infection of the eye |
-
2017
- 2017-09-19 WO PCT/US2017/052288 patent/WO2018057522A1/en not_active Ceased
- 2017-09-19 US US16/334,691 patent/US20200331984A1/en not_active Abandoned
- 2017-09-19 EP EP17853753.6A patent/EP3516063A4/en not_active Withdrawn
- 2017-09-19 JP JP2019515416A patent/JP2020501510A/ja active Pending
- 2017-09-19 AU AU2017330565A patent/AU2017330565A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501510A5 (https=) | ||
| JP6355032B2 (ja) | 新規組換え二機能性融合タンパク質、それらの調製および使用 | |
| JP7228515B2 (ja) | 多価制御性ｔ細胞調節因子 | |
| EP1326626B1 (en) | Methods for treating rheumatoid arthritis using il-17 antagonists | |
| JP2020203889A (ja) | 抗体製剤 | |
| JP2016537340A5 (https=) | ||
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2010518079A5 (https=) | ||
| JP2021533204A5 (https=) | ||
| JP2020517658A5 (https=) | ||
| JP2021514661A5 (https=) | ||
| JP2017535285A5 (https=) | ||
| AU2017201771A1 (en) | Methods and compositions for treating lupus | |
| JP2021516966A5 (https=) | ||
| JP2020502219A5 (https=) | ||
| Hansen et al. | Influence of interleukin‐6 (IL‐6) autoantibodies on IL‐6 binding to cellular receptors | |
| JP2024500870A5 (https=) | ||
| JP2022531387A (ja) | Ｃｄ８０細胞外ドメイン－ｆｃ融合タンパク質を含む医薬製剤 | |
| JP2024028756A (ja) | インターロイキン－１２とフィブロネクチンのエクストラドメインｂに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 | |
| JP2017528454A5 (https=) | ||
| JP2020502218A5 (https=) | ||
| JP2022523290A (ja) | 製剤 | |
| WO2022111612A1 (zh) | 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途 | |
| US20230174638A1 (en) | Formulations of anti-il-33 antibodies | |
| WO2023092324A1 (zh) | 多特异性配体结合分子及其应用 |